In the past Hilary A. Robbins has collaborated on articles with Brooke J. Gipson. One of their most recent publications is Original ArticleMelanoma Risk and Survival among Organ Transplant Recipients. Which was published in journal Journal of Investigative Dermatology.

More information about Hilary A. Robbins research including statistics on their citations can be found on their Copernicus Academic profile page.

Hilary A. Robbins's Articles: (3)

Original ArticleMelanoma Risk and Survival among Organ Transplant Recipients

Solid organ transplant recipients, who are medically immunosuppressed to prevent graft rejection, have increased melanoma risk, but risk factors and outcomes are incompletely documented. We evaluated melanoma incidence among 139,991 non-Hispanic white transplants using linked US transplant-cancer registry data (1987–2010). We used standardized incidence ratios (SIRs) to compare incidence with the general population and incidence rate ratios (IRRs) from multivariable Poisson models to assess risk factors. Separately, we compared post-melanoma survival among transplant recipients (n=182) and non-recipients (n=131,358) using multivariable Cox models. Among transplant recipients, risk of invasive melanoma (n=519) was elevated (SIR=2.20, 95% CI 2.01–2.39), especially for regional stage tumors (SIR=4.11, 95% CI 3.27–5.09). Risk of localized tumors was stable over time after transplantation but higher with azathioprine maintenance therapy (IRR=1.35, 95% CI 1.03–1.77). Risk of regional/distant stage tumors peaked within 4 years following transplantation and increased with polyclonal antibody induction therapy (IRR=1.65, 95% CI 1.02–2.67). Melanoma-specific mortality was higher among transplant recipients than non-recipients (hazard ratio 2.98, 95% CI 2.26–3.93). Melanoma exhibits increased incidence and aggressive behavior under transplant-related immunosuppression. Some localized melanomas may result from azathioprine, which acts synergistically with UV radiation, whereas T-cell–depleting induction therapies may promote late-stage tumors. Our findings support sun safety practices and skin screening for transplant recipients.

Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer

Highlights•Among people with HNSCC, oral HPV detection has good specificity (92%) and moderate sensitivity (72%) for HPV-positive HNSCC.•The utility of oral HPV detection to screen for HNSCC among healthy populations is probably limited, as there would be many false-positives.

Patterns of repeated anal cytology results among HIV-positive and HIV-negative men who have sex with men

AbstractBackgroundMen who have sex with men (MSM) are at increased risk for anal cancer. In cervical cancer screening, patterns of repeated cytology results are used to identify low- and high-risk women, but little is known about these patterns for anal cytology among MSM.MethodsWe analyzed Multicenter AIDS Cohort Study (MACS) data for MSM who were offered anal cytology testing annually (HIV-positive) or every 2 years (HIV-negative) for 4 years.ResultsFollowing an initial negative (normal) cytology, the frequency of a second negative cytology was lower among HIV-positive MSM with CD4 ≥ 500 (74%) or CD4 < 500 (68%) than HIV-negative MSM (83%) (p < 0.001). After an initial abnormal cytology, the frequency of a second abnormal cytology was highest among HIV-positive MSM with CD4 < 500 (70%) compared to CD4 ≥ 500 (53%) or HIV-negative MSM (46%) (p = 0.003). Among HIV-positive MSM with at least three results, 37% had 3 consecutive negative results; 3 consecutive abnormal results were more frequent among CD4 < 500 (22%) than CD4 ≥ 500 (10%) (p = 0.008).ConclusionsMore than one-third of HIV-positive MSM have consistently negative anal cytology over three years. Following abnormal anal cytology, a repeated cytology is commonly negative in HIV-negative or immunocompetent HIV-positive men, while persistent cytological abnormality is more likely among HIV-positive men with CD4 < 500.

Join Copernicus Academic and get access to over 12 million papers authored by 7+ million academics.
Join for free!

Contact us